

ANAND ET AL.
Appl. No. 10/563,042
Attny. Ref.: 620-406
Amendment After Final Rejection
February 10, 2010

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

1. (Currently Amended) A method of treating cancer in an individual comprising administering an Aurora A kinase inhibitor and a mitotic spindle assembly inhibitor to said individual, wherein [[an]] Aurora A kinase is over-expressed in the cancer cells relative to non-cancer cells.
2. (Previously Presented) A method according to claim 1 wherein said cancer is resistant to said mitotic spindle assembly inhibitor.
3. (Previously Presented) A method according to claim 1 wherein the mitotic spindle assembly inhibitor is a taxane.
4. (Previously Presented) A method according to claim 3 wherein the taxane is paclitaxel or a derivative thereof and wherein said derivative is a taxane.
5. (Currently Amended) A method according to claim 1 wherein the Aurora A kinase inhibitor is selected from the group consisting of 4- (4- (N benzoylamino) anilino) -6- methoxy -7- (3- (1 morpholino) propoxy) quinazoline and Hesperadin.
6. (Currently Amended) A method according to claim 1 wherein the Aurora A kinase inhibitor is an antibody molecule which specifically binds to an Aurora A kinase.
7. (Currently Amended) A method according to claim 1 wherein the Aurora A kinase inhibitor is a sense or anti-sense nucleic acid molecule that inhibits the expression of an Aurora A kinase.
8. (Previously Presented) A method according to claim 1 wherein the cancer is an epithelial cancer.

ANAND ET AL.
Appl. No. 10/563,042
Attny. Ref.: 620-406
Amendment After Final Rejection
February 10, 2010

9. (Original) A method according to claim 8 wherein the epithelial cancer is skin, thyroid, colon, pancreas, lung, prostate, cervical, ovarian or breast cancer.

10. (Withdrawn) A method according to claim 1 wherein the cancer is liver, kidney or brain cancer.

Claims 11-51. (Canceled)